

Elisabetta Bugianesi

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2635016/elisabetta-bugianesi-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

134
papers

12,986
citations

50
h-index

113
g-index

152
ext. papers

18,465
ext. citations

8.1
avg, IF

6.59
L-index

#	Paper	IF	Citations
134	Oncostatin M is overexpressed in NASH-related hepatocellular carcinoma and promotes cancer cell invasiveness and angiogenesis.. <i>Journal of Pathology</i> , 2022 ,	9.4	2
133	Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance.. <i>JHEP Reports</i> , 2022 , 4, 100409	10.3	4
132	Metabolic subtypes of nonalcoholic fatty liver disease patients exhibit distinctive cardiovascular risk profiles.. <i>Hepatology</i> , 2022 ,	11.2	2
131	Global multi-stakeholder endorsement of the MAFLD definition.. <i>The Lancet Gastroenterology and Hepatology</i> , 2022 ,	18.8	18
130	Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.. <i>JHEP Reports</i> , 2022 , 4, 100477	10.3	2
129	Macrophage Scavenger Receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease.. <i>Journal of Hepatology</i> , 2021 ,	13.4	4
128	Clinical and Patient-Reported Outcomes From Patients With Nonalcoholic Fatty Liver Disease Across the World: Data From the Global NASH/NAFLD Registry. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	4
127	The Impact of Dysmetabolic Sarcopenia Among Insulin Sensitive Tissues: A Narrative Review. <i>Frontiers in Endocrinology</i> , 2021 , 12, 716533	5.7	6
126	The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. <i>Lancet, The</i> , 2021 ,	40	12
125	Hepatocyte-Specific Deletion of HIF2 β Prevents NASH-Related Liver Carcinogenesis by Decreasing Cancer Cell Proliferation. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2021 ,	7.9	2
124	Insulin Resistance across the Spectrum of Nonalcoholic Fatty Liver Disease. <i>Metabolites</i> , 2021 , 11,	5.6	12
123	NASH limits anti-tumour surveillance in immunotherapy-treated HCC. <i>Nature</i> , 2021 , 592, 450-456	50.4	164
122	Association between gut permeability and insulin resistance: Any role for zonulin in patients with non-alcoholic fatty liver disease?. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021 , 45, 101614	2.4	1
121	Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: A cost-of-illness analysis. <i>Liver International</i> , 2021 , 41, 1227-1242	7.9	20
120	Inflammatory Bowel Disease Nurse-Practical Messages.. <i>Nursing Reports</i> , 2021 , 11, 229-241	0.8	0
119	Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. <i>Gut</i> , 2021 ,	19.2	31
118	Biomarkers of Oncogenesis, Adipose Tissue Dysfunction and Systemic Inflammation for the Detection of Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease. <i>Cancers</i> , 2021 , 13,	6.6	9

117	Natural history of NASH. <i>Liver International</i> , 2021 , 41 Suppl 1, 78-82	7.9	4
116	A Global Survey of Physicians Knowledge About Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	9
115	Switching from Biosimilar to Biosimilar Adalimumab, Including Multiple Switching, in Crohn's Disease: A Prospective Study. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	3
114	Outcomes and potential surrogate markers for future clinical trials of non-alcoholic steatohepatitis cirrhosis. <i>Liver International</i> , 2021 , 41, 1999-2008	7.9	2
113	Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 806-815.e5	6.9	21
112	Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores. <i>Journal of Hepatology</i> , 2021 , 74, 775-782	13.4	50
111	Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach?. <i>Gut</i> , 2021 ,	19.2	27
110	The Clinical Role of Serum Epidermal Growth Factor Receptor 3 in Hepatitis C Virus-Infected Patients with Early Hepatocellular Carcinoma. <i>Biology</i> , 2021 , 10,	4.9	2
109	Copy number variation and expression of exportin-4 associates with severity of fibrosis in metabolic associated fatty liver disease. <i>EBioMedicine</i> , 2021 , 70, 103521	8.8	5
108	Differences between current clinical guidelines for screening, diagnosis and management of nonalcoholic fatty liver disease and real-world practice: a targeted literature review. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021 , 15, 1253-1266	4.2	3
107	Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2021 , 161, 1657-1669	13.3	17
106	Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2021 , 75, 786-794	13.4	21
105	Management of non-alcoholic fatty liver disease. <i>BMJ, The</i> , 2021 , 372, m4747	5.9	31
104	The Usefulness of Microencapsulated Sodium Butyrate Add-On Therapy in Maintaining Remission in Patients with Ulcerative Colitis: A Prospective Observational Study. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	10
103	Alpha-Fetoprotein, Protein Induced by Vitamin K Absence or Antagonist II and Glypican-3 for the Detection and Prediction of Hepatocellular Carcinoma in Patients with Cirrhosis of Viral Etiology. <i>Cancers</i> , 2020 , 12,	6.6	7
102	Serum Interleukin-6 and -8 as Predictors of Response to Vedolizumab in Inflammatory Bowel Diseases. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	7
101	Mechanisms for increased risk of diabetes in chronic liver diseases. <i>Liver International</i> , 2020 , 40, 2489-2499	7.9	5
100	On-Treatment Decrease of Serum Interleukin-6 as a Predictor of Clinical Response to Biologic Therapy in Patients with Inflammatory Bowel Diseases. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	16

99	Fatty liver disease: putting the spotlight on a silent menace for young adults. <i>The Lancet Gastroenterology and Hepatology</i> , 2020 , 5, 236-238	18.8	6
98	Analytical and clinical evaluation of a novel assay for anti-HBc IgG measurement in serum of subjects with overt and occult HBV infection. <i>Diagnostic Microbiology and Infectious Disease</i> , 2020 , 96, 114985	2.9	7
97	A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. <i>Journal of Hepatology</i> , 2020 , 73, 202-209	13.4	764
96	Genetic variation in the TLL1 gene is not associated with fibrosis in patients with metabolic associated fatty liver disease. <i>PLoS ONE</i> , 2020 , 15, e0243590	3.7	0
95	qFIBS: An Automated Technique for Quantitative Evaluation of Fibrosis, Inflammation, Ballooning, and Steatosis in Patients With Nonalcoholic Steatohepatitis. <i>Hepatology</i> , 2020 , 71, 1953-1966	11.2	27
94	Prognostic Role of Serum Cytokeratin-19 Fragment (CYFRA 21-1) in Patients with Hepatocellular Carcinoma. <i>Cancers</i> , 2020 , 12,	6.6	6
93	The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease. <i>Contemporary Clinical Trials</i> , 2020 , 98, 106175	2.3	28
92	Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis. <i>Science Translational Medicine</i> , 2020 , 12,	17.5	51
91	Interplay between Oxidative Stress and Metabolic Derangements in Non-Alcoholic Fatty Liver Disease: The Role of Selenoprotein P. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	11
90	Clinical Response and Changes of Cytokines and Zonulin Levels in Patients with Diarrhoea-Predominant Irritable Bowel Syndrome Treated with ES1 for 8 or 12 Weeks: A Preliminary Report. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	6
89	Presence of Serum Antinuclear Antibodies Does Not Impact Long-Term Outcomes in Nonalcoholic Fatty Liver Disease. <i>American Journal of Gastroenterology</i> , 2020 , 115, 1289-1292	0.7	5
88	Macrophage Markers Do Not Add to the Prediction of Liver Fibrosis by Transient Elastography in Patients With Metabolic Associated Fatty Liver Disease. <i>Frontiers in Medicine</i> , 2020 , 7, 616212	4.9	1
87	Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation. <i>Hepatology</i> , 2020 , 71, 1213-1227	12.7	104
86	Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort. <i>Journal of Hepatology</i> , 2020 , 73, 505-515	13.4	113
85	The next decade of metabolism. <i>Nature Metabolism</i> , 2019 , 1, 2-4	14.6	3
84	Prevalence and long-term outcomes of non-alcoholic fatty liver disease among elderly individuals from the United States. <i>BMC Gastroenterology</i> , 2019 , 19, 56	3	31
83	Rare Pathogenic Variants Predispose to Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. <i>Scientific Reports</i> , 2019 , 9, 3682	4.9	42
82	Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 2310-2319.e6	6.9	42

81	A variant in the MICA gene is associated with liver fibrosis progression in chronic hepatitis C through TGF- β dependent mechanisms. <i>Scientific Reports</i> , 2019 , 9, 1439	4.9	6
80	Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 748-755.e3	6.9	311
79	Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2019 , 71, 1012-1021	13.4	66
78	Adalimumab Therapy Improves Intestinal Dysbiosis in Crohn's Disease. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	32
77	Clinical outcomes in chronic hepatitis C long-term responders to pre-direct antiviral agents: a single-center retrospective study. <i>Minerva Medica</i> , 2019 , 110, 401-409	2.2	9
76	Oncostatin M, A Profibrogenic Mediator Overexpressed in Non-Alcoholic Fatty Liver Disease, Stimulates Migration of Hepatic Myofibroblasts. <i>Cells</i> , 2019 , 9,	7.9	9
75	Effects of Alcohol Consumption and Metabolic Syndrome on Mortality in Patients With Nonalcoholic and Alcohol-Related Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 1625-1633.e1	6.9	56
74	Altered Metabolic Profile and Adipocyte Insulin Resistance Mark Severe Liver Fibrosis in Patients with Chronic Liver Disease. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	7
73	Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2019 , 394, 2184-2196	40	425
72	Impact of Obesity and Alanine Aminotransferase Levels on the Diagnostic Accuracy for Advanced Liver Fibrosis of Noninvasive Tools in Patients With Nonalcoholic Fatty Liver Disease. <i>American Journal of Gastroenterology</i> , 2019 , 114, 916-928	0.7	27
71	Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. <i>Hepatology</i> , 2019 , 69, 2672-2682	11.2	557
70	A spotlight on pathogenesis, interactions and novel therapeutic options in NAFLD. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019 , 16, 80-82	24.2	19
69	NASH in Lean Individuals. <i>Seminars in Liver Disease</i> , 2019 , 39, 86-95	7.3	77
68	A polymorphism in the Irisin-encoding gene (FNDC5) associates with hepatic steatosis by differential miRNA binding to the 3'UTR. <i>Journal of Hepatology</i> , 2019 , 70, 494-500	13.4	46
67	Hypoxia-inducible factor 2 α drives nonalcoholic fatty liver progression by triggering hepatocyte release of histidine-rich glycoprotein. <i>Hepatology</i> , 2018 , 67, 2196-2214	11.2	42
66	Reply to "Definition of Small for Gestational Age and Low Birthweight". <i>American Journal of Gastroenterology</i> , 2018 , 113, 442	0.7	
65	Significant improvement of glycemic control in diabetic patients with HCV infection responding to direct-acting antiviral agents. <i>Journal of Medical Virology</i> , 2018 , 90, 320-327	19.7	57
64	Usefulness of the index of NASH - ION for the diagnosis of steatohepatitis in patients with non-alcoholic fatty liver: An external validation study. <i>Liver International</i> , 2018 , 38, 715-723	7.9	15

63	Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018 , 15, 11-20	24.2	1902
62	Reply. <i>Hepatology</i> , 2018 , 67, 1178-1180	11.2	
61	Should we undertake surveillance for HCC in patients with NAFLD?. <i>Journal of Hepatology</i> , 2018 , 68, 326-334	13.4	93
60	Altered amino acid concentrations in NAFLD: Impact of obesity and insulin resistance. <i>Hepatology</i> , 2018 , 67, 145-158	11.2	162
59	The Impact of Metabolic Syndrome on the Outcome of NASH: Cirrhosis, Hepatocellular Carcinoma, and Mortality. <i>Current Hepatology Reports</i> , 2018 , 17, 336-344	1	0
58	An internet-based approach for lifestyle changes in patients with NAFLD: Two-year effects on weight loss and surrogate markers. <i>Journal of Hepatology</i> , 2018 , 69, 1155-1163	13.4	25
57	Non-invasive prediction of esophageal varices by stiffness and platelet in non-alcoholic fatty liver disease cirrhosis. <i>Journal of Hepatology</i> , 2018 , 69, 878-885	13.4	75
56	Metabolic syndrome and severity of fibrosis in nonalcoholic fatty liver disease: An age-dependent risk profiling study. <i>Liver International</i> , 2017 , 37, 1389-1396	7.9	26
55	IFN- β , not IFN- α , likely mediates IFNL3-IFNL4 haplotype-dependent hepatic inflammation and fibrosis. <i>Nature Genetics</i> , 2017 , 49, 795-800	36.3	72
54	Low Birthweight Increases the Likelihood of Severe Steatosis in Pediatric Non-Alcoholic Fatty Liver Disease. <i>American Journal of Gastroenterology</i> , 2017 , 112, 1277-1286	0.7	22
53	Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease. <i>Cancer Medicine</i> , 2017 , 6, 1930-1940	4.8	29
52	Use of HOMA-IR to diagnose non-alcoholic fatty liver disease: a population-based and inter-laboratory study. <i>Diabetologia</i> , 2017 , 60, 1873-1882	10.3	51
51	MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals. <i>Scientific Reports</i> , 2017 , 7, 4492	4.9	131
50	Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis. <i>American Journal of Gastroenterology</i> , 2017 , 112, 740-751	0.7	273
49	Microvesicles released from fat-laden cells promote activation of hepatocellular NLRP3 inflammasome: A pro-inflammatory link between lipotoxicity and non-alcoholic steatohepatitis. <i>PLoS ONE</i> , 2017 , 12, e0172575	3.7	38
48	Nonalcoholic fatty liver disease: cause or consequence of type 2 diabetes?. <i>Liver International</i> , 2016 , 36, 1563-1579	7.9	96
47	Obesity: Childhood obesity: time bomb for future burden of chronic liver disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2016 , 13, 506-7	24.2	2
46	MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C. <i>Nature Communications</i> , 2016 , 7, 12757	17.4	73

45	Imaging biomarkers for steatohepatitis and fibrosis detection in non-alcoholic fatty liver disease. <i>Scientific Reports</i> , 2016 , 6, 31421	4.9	22
44	The macrophage activation marker sCD163 is associated with morphological disease stages in patients with non-alcoholic fatty liver disease. <i>Liver International</i> , 2016 , 36, 1549-57	7.9	67
43	Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes. <i>Hepatology</i> , 2016 , 64, 34-46	11.2	65
42	FibroGENE: A gene-based model for staging liver fibrosis. <i>Journal of Hepatology</i> , 2016 , 64, 390-398	13.4	55
41	MERTK rs4374383 polymorphism affects the severity of fibrosis in non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2016 , 64, 682-90	13.4	79
40	Treatment of type 2 diabetes mellitus by viral eradication in chronic hepatitis C: Myth or reality?. <i>Digestive and Liver Disease</i> , 2016 , 48, 105-11	3.3	42
39	A "systems medicine" approach to the study of non-alcoholic fatty liver disease. <i>Digestive and Liver Disease</i> , 2016 , 48, 333-42	3.3	42
38	Progression and Natural History of Nonalcoholic Fatty Liver Disease in Adults. <i>Clinics in Liver Disease</i> , 2016 , 20, 313-24	4.6	83
37	Liver Cancer: Connections with Obesity, Fatty Liver, and Cirrhosis. <i>Annual Review of Medicine</i> , 2016 , 67, 103-17	17.4	293
36	Pathophysiology of Non Alcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , 2016 , 17,	6.3	88
35	Different Serum Free Fatty Acid Profiles in NAFLD Subjects and Healthy Controls after Oral Fat Load. <i>International Journal of Molecular Sciences</i> , 2016 , 17, 479	6.3	51
34	Non-Alcoholic Fatty Liver Disease and Extra-Hepatic Cancers. <i>International Journal of Molecular Sciences</i> , 2016 , 17,	6.3	111
33	Renin-Angiotensin System Inhibitors, Type 2 Diabetes and Fibrosis Progression: An Observational Study in Patients with Nonalcoholic Fatty Liver Disease. <i>PLoS ONE</i> , 2016 , 11, e0163069	3.7	45
32	Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease. <i>Hepatology</i> , 2016 , 63, 107-16	11.2	42
31	Cytokeratin 18-Aspartate396 apoptotic fragment for fibrosis detection in patients with non-alcoholic fatty liver disease and chronic viral hepatitis. <i>Digestive and Liver Disease</i> , 2016 , 48, 55-61	3.3	16
30	EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease: disease mongering or call to action?. <i>Diabetologia</i> , 2016 , 59, 1145-7	10.3	11
29	Reply to "Chronic hepatitis C and diabetes: More questions than answers with the new direct acting antiviral drugs?". <i>Digestive and Liver Disease</i> , 2016 , 48, 1101-2	3.3	
28	Risk of microangiopathy in type 2 diabetes mellitus patients with or without chronic hepatitis C: Results of a retrospective long-term controlled cohort study. <i>Digestive and Liver Disease</i> , 2015 , 47, 405-10	3.3	6

27	Interferon- γ 12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease. <i>Nature Communications</i> , 2015 , 6, 6422	17.4	127
26	Systemic Complications of Nonalcoholic Fatty Liver Disease: When the Liver Is Not an Innocent Bystander. <i>Seminars in Liver Disease</i> , 2015 , 35, 236-49	7.3	54
25	Ovarian senescence increases liver fibrosis in humans and zebrafish with steatosis. <i>DMM Disease Models and Mechanisms</i> , 2015 , 8, 1037-46	4.1	42
24	The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease. <i>Liver International</i> , 2015 , 35, 1566-73	7.9	94
23	Nonalcoholic fatty liver disease. <i>Nature Reviews Disease Primers</i> , 2015 , 1, 15080	51.1	366
22	Carbohydrate intake and nonalcoholic fatty liver disease: fructose as a weapon of mass destruction. <i>Hepatobiliary Surgery and Nutrition</i> , 2015 , 4, 109-16	2.1	68
21	NAFLD and Hepatocellular Carcinoma: How Big a Problem is This Really?. <i>Current Hepatology Reports</i> , 2014 , 13, 113-118	1	4
20	379 Characteristics and Long-Term Prognosis of Lean Patients With Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2014 , 146, S-909	13.3	64
19	Serum ferritin levels lack diagnostic accuracy for liver fibrosis in patients with nonalcoholic fatty liver disease. <i>Clinical Gastroenterology and Hepatology</i> , 2014 , 12, 1163-1169.e1	6.9	31
18	Glucokinase regulatory protein gene polymorphism affects liver fibrosis in non-alcoholic fatty liver disease. <i>PLoS ONE</i> , 2014 , 9, e87523	3.7	83
17	Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. <i>Nutrients</i> , 2013 , 5, 1544-60	6.7	474
16	Hepatic and cardiac steatosis: are they coupled?. <i>Heart Failure Clinics</i> , 2012 , 8, 663-70	3.3	14
15	Reliability of transient elastography for the detection of fibrosis in non-alcoholic fatty liver disease and chronic viral hepatitis. <i>Journal of Hepatology</i> , 2011 , 54, 64-71	13.4	192
14	Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011 , 26, 1536-43	4	115
13	HBV and HCV infection in type 2 diabetes mellitus: a survey in three diabetes units in different Italian areas. <i>Acta Diabetologica</i> , 2011 , 48, 337-343	3.9	20
12	Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C. <i>Hepatology</i> , 2009 , 50, 697-706	11.2	117
11	NASH and the risk of cirrhosis and hepatocellular carcinoma in type 2 diabetes. <i>Current Diabetes Reports</i> , 2007 , 7, 175-80	5.6	46
10	Reply:. <i>Hepatology</i> , 2006 , 43, 1168-1169	11.2	16

9	Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and hepatic steatosis. <i>Hepatology</i> , 2006 , 44, 1648-55	11.2	126
8	A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. <i>American Journal of Gastroenterology</i> , 2005 , 100, 1082-90	0.7	516
7	Insulin resistance: a metabolic pathway to chronic liver disease. <i>Hepatology</i> , 2005 , 42, 987-1000	11.2	601
6	Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005 , 90, 3498-504 ^{5,6}	5.6	322
5	Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. <i>Hepatology</i> , 2004 , 39, 179-87	11.2	342
4	Uric acid levels and liver fibrosis in nonalcoholic fatty liver disease. <i>Hepatology</i> , 2004 , 39, 1749-1749	11.2	5
3	Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): treatment. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , 2004 , 18, 1105-16	2.5	26
2	Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. <i>Gastroenterology</i> , 2002 , 123, 134-40	13.3	1170
1	Diabetes and NAFLD: Why is the Connection Important?62-70		